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Abstract
Objectives. Viruses may contribute to RA. This prompted us to monitor viral load and response to
anti-CD20 therapy in RA patients.
Methods. Blood and bone marrow from 35 RA patients were analysed for CMV, EBV, HSV-1, HSV-2,
parvovirus B19 and polyomavirus using real-time PCR before and 3 months after rituximab (RTX) treat-
ment and related to the levels of autoantibodies and B-cell depletion. Clinical response to RTX was
defined as decrease in the 28-joint disease activity score (DAS-28) >1.3 at 6 months.
Results. Before RTX treatment, EBV was identified in 15 out of 35 patients (EBV-positive group), of which
4 expressed parvovirus. Parvovirus was further detected in eight patients (parvo-positive group). Twelve
patients were negative for the analysed viruses. Following RTX, EBV was cleared, whereas parvovirus was
unaffected. Eighteen patients were responders, of which 12 were EBV positive. The decrease in the
DAS-28 was significantly higher in EBV-positive group compared with parvo-positive group (P=0.002)
and virus-negative patients (P=0.04). Most of EBV-negative patients that responded to RTX (75%)
required retreatment within the following 11 months compared with only 8% of responding
EBV-positive patients. A decrease of RF, Ig-producing cells and CD19
+ B cells was observed following
RTX but did not distinguish between viral infections. However, EBV-infected patients had significantly
higher levels of Fas-expressing B cells at baseline as compared with EBV-negative groups.
Conclusions. EBV and parvovirus genomes are frequently found in bone marrow of RA patients. The
presence of EBV genome was associated with a better clinical response to RTX. Thus, presence of EBV
genome may predict clinical response to RTX.
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Introduction
Several viral infections have been observed before onset
of RA or flares in an already established RA [1]. Human
parvovirus B19 is among the commonest [1], but other
viruses belonging to the herpes family including EBV [2],
CMV [3, 4] and HSV [5] have also been suggested to
participate in the aetiopathogenesis of rheumatic dis-
eases. The arthritogenic viral nucleic acid double-
stranded RNA [6], which is expressed during replication
by most viruses [7], is also found in the synovium of RA
patients together with EBV, where it may contribute to
accelerated inflammation and erosivity [8]. This is one
way in which viral infections may contribute to arthritis.
EBV can persist in the bone marrow (mainly in B cells)
[9] and parvovirus replicates predominantly in erythroid
precursors in the bone marrow [10]. HSV-1, HSV-2 and
polyomavirus also persists at haematopoetic sites includ-
ing the bone marrow [11], whereas CMVs have a broad
cell and tissue tropism including the bone marrow [12]. In
RA, a direct traffic between the bone marrow and the
synovium is possible due to penetration of the cortical
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bone marrow could thus aggravate RA or precipitate
flares by increasing the inflammatory drive in adjacent
joints.
Several mechanisms have been proposed to explain the
arthritogenicity of a viral infection. It has been suggested
that sequence homology between gp110 of EBV and the
shared epitope (SE) in the MHC Class II gene could be a
link between RA and EBV. Tolerance to the SE
DRB1*0401 HV3 peptide (amino acid sequence QKRAA)
in people who express HLA-DRB1*0401 [14], could impair
anti-gp110 immunity and thereby the ability of SE carriers
to fight EBV infections. This could explain the altered
EBV response in RA patients as compared with healthy
individuals: EBV-infected RA patients have a diminished
cytotoxic T-cell response to EBV as compared with
non-RA controls [15, 16], increased number of EBV-
infected B cells and high prevalence of antibodies to dif-
ferent EBV antigens [17]. Of these, antibodies to EBNA-1
cross-react with denatured collagen and keratin, two pos-
sible autoantigens in RA. Also, EBV infection may trans-
form infected B cells into antibody-secreting plasma cells,
thus increasing the likelihood of activating autoreactive
B-cell clones [18].
Mechanistic theories of how other viruses may contrib-
ute to arthritis are numerous [1], but all evidence gathered
so far is only circumstantial. A complicating factor in
determining the role of viruses for the actual development
of arthritis is the fact that today’s RA patients often stand
on immunosuppressive treatment that may expose them
to an increased risk of viral infection [19]. Widely spread
viruses may, therefore, become particularly important as a
pathogen in immunocompromised patients. Infections
acquired or elicited viral reactivation due to immunosup-
pressive treatment could thus confound aetiological
agents and opportunistic infections. Also, immunosup-
pressive treatment that alters immune responses to
pre-existing viral infections could theoretically influence
response to treatment.
We therefore set out to determine: (i) the presence of
parvovirus B19, EBV, polyomavirus, HSV-1 and HSV-2
and CMV before and 3 months after immunosuppressive
treatment with rituximab (RTX); and (ii) the importance of
specific viral infections for response to RTX. RTX is an
mAb therapy that selectively depletes B cells by targeting
the B-cell surface antigen CD20. B-cell depletion, in com-
bination with MTX, has been shown to be a highly efficient
therapy in patients with insufficient response to conven-
tional DMARDs and non-responsiveness to anti-TNF-a
therapy [20–23]. Upon treatment, CD20-expressing B
cells are depleted [24], but the mechanism of B-cell de-
pletion is not fully understood but may involve
CD20-dependent pre-sensitization before Fas-mediated
(CD95) apoptosis [25]. Intriguingly, there is no clear
consensus regarding correlation between response
to RTX and efficient depletion of B cells. Earlier reports
have indicated both differences [26] and absence of
differences [27] in B-cell depletion efficacy, and distinct
repletion patterns of B-cell subpopulations in
responders/non-responders [28, 29]. For example,
unswitched memory B cells (IgD
+, CD27
+) were reported
to repopulate the circulation faster after B-cell depletion in
non-responders vs responders [29].
Our findings clearly show that RA patients having
EBV replication at baseline, not only cleared their EBV
load, but responded significantly better to the RTX
treatment and presented a longer lasting response than
patients who do not have EBV replication in the bone
marrow.
Materials and methods
Patients and treatment
Thirty-five patients were included in the study (Table 1). All
patients gave written informed consent to participate. The
study was approved by the Regional Ethics Board in
Gothenburg (Dnr 633–07). At baseline, 33 patients were
on MTX, 1 on AZA and 1 on chlorambucil. Of the patients,
34 were earlier non-responders to anti-TNF-a treatment.
All patients commenced anti-CD20 treatment by RTX
(F Hoffman-La Roche Ltd, Basel, Switzerland) by infusion
of 1000mg followed by 1000mg 2 weeks later.
The 28-joint disease activity score (DAS-28) [30] based
on the ESR was performed at baseline, and at planned
revisits at 3 and 6 months (32 of 35 patients fulfilled both
revisits). Response was determined by the change in the
DAS-28 and the European League Against Rheumatism
response criteria, where an individual patient presenting
a decrease in the DAS-28>1.3 is defined as a responder
to the therapy [31]. Patient characteristics are described in
Table 1.
Blood and bone marrow samples
Ten millilitres of heparinized bone marrow aspirates were
collected from crista iliaca before the RTX infusion, where-
after mononuclear cells were isolated using a gradient
separation on Lymphoprep (Axis-Shield PoC As, Oslo,
Norway). Following separation, cells were kept on ice for
a maximum of 2h or immediately stained for flow cyto-
metric analyses. Peripheral blood was obtained by veno-
puncture from the cubital vein directly in a sterile
heparinized vacuum container.
Real-time PCR
Bone marrow and blood samples were evaluated for pres-
ence of CMV, EBV, HSV-1, HSV-2, parvovirus and poly-
omavirus at baseline and 3 months later using real-time
PCR. Extraction of DNA from 200ml of serum or from
200ml aspirated bone marrow was done in a Magnapure
LC instrument (Roche Applied Science, Mannheim,
Germany), using the DNA Isolation Kit I (Roche).
Real-time PCR, using primers and probes described in
Table 2, was then performed on an ABI 7000 or 7900 in-
strument (Applied Biosystems, Foster City, CA, USA), with
10ml of extracted sample in a reaction volume of 50ml,
including 25ml of Universal Master Mix with Uracil
N-glycosylase (Applied Biosystems). Quantification was
obtained from a plot of Ct-values for a serial dilution of
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with inserts of the targeted viral region. The real-time
PCR assays have ranges of linear detection spanning
from 200–400 to 10 million copies/ml as determined by
testing of serial dilution of plasmids with viral inserts.
Determination of RF, anti-cyclic citrullinated peptides
and Ig-secreting cells
Blood samples were evaluated for total levels of IgG,
IgM and IgA using nephelometry and for RF of the IgG,
IgM and IgA isotypes by an ELISA (Hycor Biomedical
Ltd, Penicuit, UK) and for anti-cyclic citrullinated peptides
(anti-CCP) antibodies of the IgG isotype by ELISA
(Eurodiagnostica, Malmo ¨, Sweden) following the manufac-
turer’s instructions. The level of RF was calculated using
serial dilutions of the standards provided in the kit
and expressed in IU/ml. Levels of RF >50IU/ml were
considered positive. The number of IgG-, IgM- and
IgA-secreting cells was evaluated in blood using the
ELISpot technique.
Identification of SE carriers
The presence of HLA-DRB1 (DRB1*01) allele was evalu-
ated using PCR amplification as described [32]. The gen-
otyping was done at the Regional Blood Center,
Sahlgrenska University Hospital, Go ¨teborg.
Flow cytometry analysis
To determine alterations in B-cell phenotype, we used
mouse anti-human mAbs in different fluorochromatic
conjugations (phycoerythrin, FITC, allophycocyanin, peri-
dinin–chlorophyll–protein or pacific blue) as well as in dif-
ferent combinations, as described by Rehnberg et al. [33].
The following antibodies were used: anti-CD27 (LI28),
anti-CD95 (BD-Bioscience, Erembrogdem, Belgium),
anti-CD19 (HIB19; eBioscience, San Diego, CA, USA)
and anti-IgD F0059 (Dakocytomation, Glostrup,
TABLE 1 Clinical, demographic characteristics of patients with RA
Parameter
EBV positive
(n=15)
a
ParvoB19 positive
(n=8)
a
Virus negative
(n=12) P-value
*
Age, mean (range), years 61.1 (44–81) 57.3 (43–79) 54.2 (29–73) 0.18
Kr
Gender, female/male 14/1 7/1 9/3 0.41
F
Disease duration, mean (range), years 10.7 (3–31) 17.8 (3–33) 13.9 (3–43) 0.30
Kr
RF, positive
b
At baseline, n (%) 13 (87) 8 (100) 8 (67) 0.16
F
At 6 months follow-up, n (%) 9 (60) 2 (25) 5 (41) 0.28
F
DAS-28
At baseline, median (range) 5.90 (4.8–6.77) 5.50 (4.45–6.74) 6.21 (5.03–6.94) 0.23
AN
At 6 months follow-up, median (range) 3.95 (2.16–5.97) 4.08 (2.76–5.52) 4.86 (2.7–6.37) 0.26
AN
Change DAS28>1.3
c 12 patients (80%) 1 patient (12.5%) 5 patient (42%) 0.007
F
DMARD treatment
MTX, mg/week 14 (17) 7 (19.6) 12 (16)
Chlorambucil 1 0 0
AZA 0 1 0
HLA-DRB1 carriers,
d n (%) 6/13 (46) 3/8 (37.5) 1/12 (8) 0.14
F
Anti-CCP, median (range), U/ml 24058 (2236–400000) 16185 (1163–34612) 15689 (1000–400000) 0.41
Kr
aFour patients were positive for both EBV and parvoB19 viruses in the bone marrow and assigned to the EBV-positive group.
bRF positivity is determined as >50 U/ml of RF of IgA, IgG or IgM isotype.
cMean change (95% CI) in DAS-28 is 1.72 (1.19,
2.25) (EBV positive), 1.24 (0.07, 2.4) (parvoB19 positive) and 1.34 (0.71, 1.96) (virus negative).
dThirty-three of the 35 patients
were analysed for presence of HLA-DRB1. *Comparisons between all three groups. P-values inferior to 0.05 were regarded
significant. AN: one-way ANOVA; F: Fisher’s extended exact test; Kr: Kruskal–Wallis.
TABLE 2 Primers and probes used in real-time PCR
ID Seq.
EBV_F
a GGAACCTGGTCATCCTTTGC
EBV_R
a ACGTGCATGGACCGGTTAAT
EBV_FAM
a CGCAGGCACTCGTACTGCTCGCT
CMV_F TGATCACTGTTCTCAGCCACAAT
CMV_R TCCTCTGATTCTCTGGTGTCACC
CMV_FAM CCCGCACTATCCCTCTGTCCTCA
HSV1_F
b GCAGTTTACGTACAACCACATACAGC
HSV2_F
b TGCAGTTTACGTATAACCACATACAGC
HSV1 and 2_R
b AGCTTGCGGGCCTCGTT
HSV1_FAM
b CGGCCCAACATATCGTTGACATGGC
HSV2_FAM
b CGCCCCAGCATGTCGTTCACGT
ParvoB_F
c AAGCCGTGTGCACCCATT
ParvoBgt2_R GGTACAGGAGGACGGTTGGTTA
ParvoBgt1
and 3_R
c
TGGTACTGGTGGGCGTTTAGTTA
ParvoB_FAM
c ACACTCCCCACCGTGCCCTCA
Polyoma_F GGAAAGTCTTTAGGGTCTTCTACCTTT
Polyoma_R GGTGCCAACCTATGGAACAGA
Polyoma_FAM TCATCACTGGCAAACATWTCTTCATGGCAAA
All probes were labelled with 50 FAM (6-carboxyfluorescein)
and 30 TAMRA (6-carboxytetramethyl-rhodamine). The poly-
oma PCR detects both BK and JC viruses. As described by
aNiesters et al. [43],
bNamvar et al. [44] and
cKno ¨ll et al. [45].
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concentrations.
Statistical analysis
Categorical values (proportions in any number of different
groups) were compared using an extended version of
Fisher’s exact test (Stata v11.0; StataCorp LP, College
Station, TX, USA) to allow for small expected cell
counts. Numerical parameters between two and three dif-
ferent groups were compared using Student’s t-test and
one-way ANOVA, respectively (Prism 5.04; GraphPad
Software Inc., La Jolla, CA). When the assumptions
of the t-test or ANOVA were not met, appropriate
non-parametric alternatives were considered (Wilcoxon
rank-sum test and Kruskal–Wallis). In Table 1, each
given P-value is followed by an indication of the statistical
test used.
Results
EBV and parvovirus B19 are frequently detected in
bone marrow of RA patients
At baseline, 15 (43%) of 35 patients had EBV infection in
bone marrow (Fig. 1 and Table 1). Of these 15 patients,
7 had detectable levels of EBV genome even in blood
samples (Fig. 1). Four of the patients with EBV infection
in the bone marrow also expressed parvovirus B19
genome in bone marrow. The parvovirus B19 genome
was further detected in the bone marrow, but never in
blood (data not shown), of eight EBV-negative patients
(Table 1). Interestingly, all EBV-positive bone marrow
and blood samples obtained 3 months following RTX
treatment were converted to EBV negative (Fig. 1). In con-
trast, parvovirus genome was still preserved 3 months
later in all bone marrow samples that were parvo-positive
at baseline. One EBV-positive patient was positive for
CMV in blood, whereas none had polyomavirus or
HSV-1 or HSV-2 (data not shown). Patients that did not
express any of the analysed viruses in bone marrow or
blood constituted 34% (n=12; Table 1).
Following baseline findings in bone marrow, the pa-
tients were divided into EBV-positive group (patients ex-
pressing EBV in bone marrow, n=15), parvo-positive
group (patients expressing parvovirus but not EBV in
bone marrow, n=8) and virus-negative group (n=12;
Table 1). The three groups showed no difference with re-
spect to age, gender and disease duration or disease ac-
tivity of RA at baseline (Table 1). For some comparisons,
the parvo-positive group and virus-negative group were
combined into an EBV-negative group. Also, the EBV
genome load showed no correlation to the baseline
DAS-28 levels (data not shown).
The existing sequence homology between the antigenic
glycoprotein gp110 of EBV and the RA-associated SE in
HLA-DR (amino acid sequence QKRAA), prompted us to
compare the occurrence of SE (DRB1*01) and EBV infec-
tion. In all, 33% of the analysed patients expressed the SE
(DRB1*01) epitope (Table 1). Among these, we observed a
higher percentage of SE carriers among EBV-positive
patients; 6 (46%) of 13 analysed EBV-positive patients
expressed HLA-DRB1 allele, whereas among EBV-
negative patients, only 5 (25%) of 20 analysed patients
expressed this SE allele (non-significant, Table 1).
EBV positivity correlates to a better clinical response
to RTX therapy
Clinical response to RTX treatment was established as a
reduction of 51.3 in the DAS-28 index. Six months after
treatment, this criteria was fulfilled by 18 (51%) of 35
patients. Age, gender or disease duration did not predict
response to therapy (data not shown). The majority of clin-
ical responders [12 (67%) of 18] were accumulated in the
EBV-positive group. Indeed, 80% of EBV-positive patients
were responders, as compared with only 42% in the
virus-negative group and 12.5% in the parvo-positive
group (P=0.007; Table 1). At baseline, the patient
groups did not differ in the DAS-28 (Table 1), whereas at
6 months post-treatment, EBV-positive had lower DAS-28
values than patients in virus-negative group (Fig. 2A).
Further analysis of the patients’ response according to
EBV positive vs non-EBV positive revealed a clear benefit
of EBV. This was reflected in a significantly higher
DAS-28 in EBV-positive patients compared with EBV-
negative patients (Fig. 2B) and an overall significantly
higher frequency of responders (white bars, Fig. 2C).
Additionally, only 1 of 12 responders in EBV-positive
group was retreated with RTX within 11 months, whereas
four of the six responders among non-EBV patients
(virus-negative group and parvo-positive group) were re-
treated within 11 months (depicted as proportion of re-
sponders by black bars in Fig. 2C). Taken together, the
presence of EBV genome in bone marrow before
FIG.1RTX therapy clears EBV genome from blood and
bone marrow. Titre of EBV in bone marrow and blood at
baseline and 3 months following start of RTX therapy in
RA patients expressing EBV at baseline (n=15of35RA
patients). Individual values are represented by dots and
the median by the horizontal line.
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RTX treatment. It may also be associated with a longer
lasting effect of RTX.
The carriers of HLA-DRB1 comprised 46% of
EBV-positive group (see above). Given the overall better
response in this group, we thus analysed if the presence
of the HLA-DRB1 allele was associated with clinical re-
sponse to RTX treatment. Of the 10 SE carriers, 6 (60%)
were clinical responders, thus comparable with the overall
response of 54%. Five (83%) of six SE carriers in
EBV-positive group were responders but only one (25%)
of four SE carriers in the EBV-negative groups was a re-
sponder, indicating that clinical response was not directly
related to the presence of HLA-DRB1.
EBV positivity and laboratory changes following
RTX treatment
RTX selectively depletes CD20-expressing B cells leaving
pre-B cells and plasma cells that do not express CD20
[24] untouched. Given the beneficial effect of EBV on re-
sponse to RTX, we therefore analysed the impact of RTX
on B cells and B-cell products in EBV-positive and
EBV-negative patients. We could not detect any differ-
ence in total Ig or RF of isotype IgA, IgM or IgG between
EBV-positive and EBV-negative patients before, at 3 or
6 months post-treatment, which was also true for
responders vs non-responders (data not shown).
Furthermore, there was no significant difference in levels
of anti-CCP antibodies or total RF between responders
and non-responders (data not shown) or EBV-positive
and EBV-negative patients (Fig. 3), although a tendency
towards higher baseline titre was observed in
EBV-positive patients. In accordance, 60% of
EBV-positive patients remained RF-positive, whereas
only 35% of EBV-negative patients (parvo-positive and
virus-negative combined) remained RF positive; Table 1).
The number of B cells, defined as CD19
+, was totally
depleted in circulation and efficiently but not entirely in
bone marrow (Fig. 4 and [33]) 3 months following RTX
therapy in all patients, irrespectively of EBV status
(Fig. 4). As the rate of repopulation of B cells of different
maturity after RTX-mediated depletion has been reported
to differ between responders and non-responders [29], we
determined the proportions of B cells of different maturity
in EBV-positive (of which 80% were clinical responders,
Fig. 2C) and EBV-negative patients (of which 30% were
clinical responders, Fig. 2C). At baseline and at 3 months
after treatment, there were no significant differences in the
proportions of bone marrow immature (CD19
+, CD27
 ,
IgD
 ), naı ¨ve (CD19
+, CD27
 , IgD
+), unswitched memory
(CD19
+, CD27
+, IgD
+) and switched memory B cells
(CD19
+, CD27
+, IgD
 ) between EBV-positive and
FIG.2Patients expressing EBV at baseline have a better clinical outcome to RTX therapy than EBV-negative patients.
(A) DAS scores [median and interquartile range (IQR)] at baseline, 3 and 6 months post-initiation of RTX in patients
expressing EBV (EBV positive), expressing only parvovirus (parvo positive) and expressing none of the analysed viruses
(virus negative) in bone marrow (*EBV positive vs virus negative, P=0.038). (B) Median reduction (and IQR) in DAS at
6 months in EBV-positive vs EBV-negative patients (*P=0.049). (C) Per cent responders (defined as a decrease in
DAS-28 > 1.3 at 6 months after initiation of RTX therapy) and proportion of responders receiving retreatment with RTX
within 11 months from baseline in EBV-positive and EBV-negative patients. There is significantly more responders (height
of the bars) in the EBV-positive group as compared with the EBV-negative group (**P=0.0034) and the proportion of
responders (the height of the black space in relation to the height of the bar) receiving retreatment within 11 months is
significantly higher in the EBV-negative group (*P=0.020).
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able as supplementary data at Rheumatology Online).I n
contrast, a population of CD19
+CD95
+ (Fas) expressing B
cells in the bone marrow was significantly higher at base-
line in EBV-positive than EBV-negative patients (Fig. 5).
As the total B-cell population (Fig. 4), this CD19
+CD95
+
population was also depleted by RTX, which thus
quenched the difference between EBV-positive and
EBV-negative patients (data not shown).
Discussion
Viruses may be part of the pathogenesis in RA. Also, sus-
ceptibility to viral infection may in fact increase in RA pa-
tients as a result of immunosuppressive therapy. This
prompted us to relate viral load in RA patients to clinical
response during the course of immunosuppressive (B-cell
depletion by RTX) therapy and immunological parameters
related to disease activity. Circulating CMV, EBV, HSV-1,
HSV-2, parvovirus B19 and polyomavirus virus was
determined in blood and bone marrow, where many
viruses can persist.
Unambiguously, B-cell depletion eradicated all traces of
EBV infection in blood and bone marrow at 3 months
post-RTX treatment, which is in line with the EBV that
mainly resides in B cells [9] and are thus removed con-
comitantly with B-cell removal. Although depletion of B
cells in the bone marrow was not complete, no genomic
EBV-DNA could be detected, indicating that EBV mainly
resides in RTX-sensitive B cells. MTX can contribute to
lower levels of EBV-DNA in circulation [34], but does
not, as RTX totally eradicates all traces of EBV. No other
detected viral infection was removed by RTX treatment.
Of note, in the group of patients expressing EBV at base-
line, the great majority (12 of 15) were responders
(DAS-28>1.3 at 6 months), whereas most non-
responders were found in the parvo-positive and
virus-negative group (14 of 17). Importantly, the DAS-28
values at baseline did not differ between patient groups,
thus confirming that the lower DAS values in
virus-negative patients at 6 months were not due to an
overall lower disease activity in EBV-positive patients. In
fact, it has been earlier reported that high EBV load cor-
relates to higher disease activity [34]. We could, however,
not find any correlation between disease activity and EBV
load. The reason for this discrepancy is not known, but
could be due to the lower number of patients included in
this study.
Our data clearly showed that patients that were carriers
of EBV had a significantly better clinical response to B-cell
depletion therapy than did patients without EBV infection
(Fig. 2). RA is a multifactorial disease and response to
various therapeutics show a great individual variation,
emphasizing that RA is a heterogeneous disease. The
identification of RTX therapy as selectively better therapy
in EBV-positive vs EBV-negative patients (Fig. 2C) indi-
cates that EBV may be an aetiopathogenic agent in a
subpopulation of RA patients.
EBV is widespread in the population but RA patients
clearly have an altered response to EBV as compared
with healthy controls. For instance, RA patients have
much higher levels of EBV-DNA [35], EBV-specific antibo-
dies [17] and a higher number of EBV-infected cells [36]
than healthy controls, indicating that RA patients have a
less efficient anti-EBV response than EBV-infected con-
trols. Our identification of EBV-infected RA patients as
better responders to RTX therapy, thus, indicates that
this RA-associated, altered EBV response may represent
a fraction of RA patients with an aetiopathogenesis pos-
sibly different from non-EBV RA patients. This fraction is
characterized by a better and more long-lasting response
to RTX therapy. EBV may contribute to RA by eliciting
anti-EBV antibody responses with putative cross-
reactivity to autoantigens (e.g. anti-EBNA1 can
cross-react with collagen or keratin) and EBV is unique
among viruses in that it may also transform B cells (irre-
spectively of antigen specificity in the B cell) to become
antibody-secreting plasma cells [18, 37]. This can occur in
the absence of the cognate antigen and secondary signals
FIG.3No significant difference in RF or anti-CCP
between EBV-positive and EBV-negative patients. Levels
of total RF (A) and anti-CCP (B) antibodies at baseline in
EBV-positive and EBV-negative group. Individual values
are represented by dots and the median by the horizontal
line.
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required for B-cell activation. EBV-transformed B cells
may also be a source of antigen-presenting cells [38].
These properties of EBV may contribute to the develop-
ment of autoantibodies and, under certain circumstances,
autoimmune disease.
Another possible link between RA and EBV is the accu-
mulated expression among RA patients of the SE, which is
homologous to EBV gp110 glycoprotein [39]. A larger pro-
portion of the EBV-positive patients (46%) expressed
HLA-DRB1 than the EBV-negative patients (20%), al-
though this was not statistically significant. There was,
however, no correlation between presence of HLA-DRB1
and disease activity or response to treatment, indicating
that response to RTX was primarily associated with the
presence of the EBV genome.
RTX is a humanized mAb directed against the CD20
antigen that is selectively expressed by B cells. RTX ther-
apy in RA patients of this study selectively depleted B
cells from blood and bone marrow compartments. The
efficacy of depletion did not differ between EBV-positive
and EBV-negative patients (Fig. 4) (and not between re-
sponders and non-responders; data not shown) indicating
that efficacy of B-cell depletion per se does not reflect
clinical response. This has not only been reported earlier
[27], but also challenged after development of a highly
sensitive assay [26]. Also, Roll et al. [29] identified distinct
repopulation patterns of circulating B cells in responders
vs non-responders. In all their patients, B cells started to
repopulate the circulation within 5.6–10.2 months, but the
unswitched memory B-cell subset (IgD
+ CD27
+) repopu-
lated faster in patients non-responsive to RTX. We there-
fore analysed the proportions of different maturational
stages of B cells in the bone marrow (where no complete
depletion occurs [33]) at baseline and 3 months after RTX.
We could, however, not detect any significant differences
regarding the proportions of B cells of different maturity, in
EBV vs non-EBV infected patients (Fig. 5) or in responders
vs non-responders [33]. Thus, the accelerated repopula-
tion of memory B cells to the circulation in non-
responders is not reflected in the proportion of residual,
non-depleted B cells in the bone marrow.
One mechanism of B-cell depletion by RTX is
Fas-mediated apoptosis [25]. In this way, RTX sensitizes
Fas-expressing CD20
+ B cells to subsequent Fas-
mediated killing [40]. At baseline, we identified significant-
ly higher proportions of B cells expressing Fas (CD95) in
EBV-positive than EBV-negative patients (Fig. 5). Higher
expression of CD95 on B cells in EBV-infected patients
could be the result of EBV-mediated up-regulation of
CD95 [41]. It is thus possible that EBV could predispose
B cells to apoptosis by RTX by up-regulation of Fas. In
general, the apoptosis machinery is perturbated in RA,
FIG.4No significant difference in RTX-mediated B-cell depletion efficiency between EBV-positive and EBV-negative
patients. Per cent of B cells (of white blood cells) defined as CD19
+ cells [(A) in blood and (B) in bone marrow] in
EBV-positive and EBV-negative group at baseline and 1–3 months after RTX treatment. The line in each box represents
the median, whereas the box represents the IQR with whiskers at ±1.5 IQR. Outliers are indicated.
FIG.5Higher baseline frequency of CD95-expressing
B cells in EBV-positive than EBV-negative patients.
Per cent CD95-expressing B cells in bone marrow of all
B cells at baseline in EBV-positive and EBV-negative
group. The line in each box represents the median,
whereas the box represents the IQR with whiskers at ±1.5
IQR. Outliers are indicated. *P=0.043.
www.rheumatology.oxfordjournals.org 1917
EBV in bone marrow of RA patientsincluding Fas-mediated apoptosis due to elevated levels
of soluble FasL [42]. EBV may overcome high levels of
soluble FasL by up-regulating the receptor (Fas), thus ren-
dering cells more susceptible to apoptosis. However, this
mechanism is not sufficient to explain why EBV-infected
patients responded better to therapy than EBV-negative
patients expressing lower levels of CD95, since B-cell de-
pletion was equally efficient regardless of EBV status.
Although the pathophysiology of CD95-expressing
B cells is unclear, high expression of CD95 on B cells
together with EBV infection could be a biomarker for
response to RTX.
In conclusion, the significantly better effect of RTX ther-
apy in EBV-positive patients as opposed to non-EBV
patients indicates that B cells are part of the RA patho-
genesis in RA patients infected with EBV, but less so in the
pathogenesis of uninfected RA patients. What defines
these B cells, apart from being infected with EBV, remains
to be determined.
Rheumatology key messages
. EBV in bone marrow of RA patients predicts
response to RTX treatment.
. RTX treatment efficiently clears EBV from the bone
marrow.
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